GlassScriptPhysician profile
Parool Mayur Kadakia
NPI 1437120698
$12,155.30
in general payments reported to CMS, 2019-2025
54 companies · $1,399 in 2025
The $1,399 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,186 · 2020: $1,013 · 2021: $1,758 · 2022: $1,950 · 2023: $2,044 · 2024: $1,805 · 2025: $1,399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,248.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,602.98 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,442.06 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,383.03 | 2019-2025 | Jardiance, Synjardy, Stiolto Respimat |
| Novo Nordisk INC | $875.08 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $822.06 | 2019-2025 | |
| Lilly USA, LLC | $767.61 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $569.81 | 2021-2024 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $534.98 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $524.28 | 2019-2022 | |
| Amgen INC. | $421.90 | 2019-2025 | Otezla, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $250.14 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $220.32 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $200.37 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Esperion Therapeutics, INC. | $193.38 | 2020-2024 | Nexletol |
| Sanofi-Aventis U.S. LLC | $180.04 | 2019-2023 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parool Kadakia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.